Reference is made to the private placement of 3,253,370 new shares towards Bomi Framroze (the "Private Placement") in Hofseth BioCare ASA, as announced on 23 March 2020.

The share capital increase relating to the Private Placement has now been registered with the Norwegian Register of Business Enterprises. The share capital has been increased with NOK 3,253,370 through issuance of 3,253,370 new shares, each with a par value of NOK 1.

The new share capital is thus NOK 329,073,881 divided by 329,073,881 shares, each with a par value of NOK 1.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

For further information, please contact:
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966

About Hofseth BioCare ASA
HBC is a Norwegian biotech company that develops high-value ingredients and finished products from Norwegian salmon off-cuts. Ingredients are further developed into discovery and pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates are development towards a Gastro-Intestinal (GI) Protective Medical Food, Medical Food to help treat age-related Sarcopenia, and future pharmaceutical clinical studies on the treatment of Anemia and NEC-IBS with Salmon Protein Hydrolysate fractions. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC can preserve the quality of lipids, proteins and calcium from fresh salmon off-cuts and trimmings.

Hofseth BioCare's headquarters are in Ålesund, Norway with branches in Oslo, Chicago, Mumbai, Menlo Park and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker "HBC". More information about Hofseth BioCare at